Callosum, a Cambridge neuroscience startup, raised a $100m seed round led by Atomico on 20 August, with Plural and DCVC participating 1. The company was founded in 2025 by Danyal Akarca and Jascha Achterberg, both neuroscientists at the University of Cambridge, and it announced partnerships with the chipmakers Cerebras and Rebellions alongside the round.
Seed rounds of this size are priced on the founders and the thesis, because there is nothing else yet to price. Callosum works on how AI systems use models and hardware together, which is why the two partnerships matter more than the usual logo slide: Cerebras builds wafer-scale accelerators and Rebellions builds inference silicon, and neither signs a research partnership with a company whose approach it cannot run on its own hardware.
Atomico led the round in a fortnight when the rest of the UK funding tail thinned sharply, so a single Cambridge seed accounted for most of one week's national total. Cambridge has produced this shape before: CuspAI, founded in 2024 by researchers in the same city, closed a $450m Series B in July on a coalition of 45 partners . Investors writing nine figures into a company founded last year are buying a scarce team rather than a revenue line. What decides whether the price holds is how fast the Cerebras and Rebellions work turns into systems other people can run.
